EUVIMEDAvasta EUVIMED
Crossref

Postoperative Radiotherapy in Advanced Stage Squamous Cell Carcinoma Requiring Maxillectomy

Randall J Harley iD, Matthew E Spector, Christopher T Wilke, Shaum Sridharan

Otolaryngology–Head and Neck Surgery · 2024

DOI: 10.1002/ohn.896 ↗

At a glance

Journal article in Otolaryngology–Head and Neck Surgery, 2024. Written by Randall J Harley and 3 co-authors. Institution: Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Major MEDLINE topics: Maxilla, Carcinoma, Squamous Cell. Cited 1 times so far (Crossref); 20 references.

AbstraktSubjectsBibliograafilised andmedCiteRelated studies

Abstract (original language)

Objective

To evaluate whether postoperative radiotherapy (PORT) improves survival among patients who received maxillectomy for pT4aN0 maxillary gingival or hard palate squamous cell carcinoma (SCC) with respect to tumor size. Study Design Retrospective analysis.

Setting

National Cancer Database from 2004 to 2019.

Methods

Included adult patients who received maxillectomy (partial, subtotal, or total) and neck dissection for treatment‐naive margin negative pT4aN0 SCC of the maxillary gingiva or hard palate. Adjusted for age, gender, race, insurance status, income, education, urban/rural, facility type, region, comorbidity index, tumor grade, and tumor extension. Inverse probability weights were incorporated into a multivariable Cox proportional hazards model. A priori post hoc subgroup analysis was performed according to tumor size.

Results

We included 416 patients who underwent maxillectomy for pT4aN0 SCC of the maxillary gingiva or hard palate (mean [standard deviation] age, 71.5 [11.3] years; male, 190 [45.7%]; tumor size 2 cm, 362 [87%]). Overall, 49.3% of patients received PORT (205 patients). PORT was associated with a 50% improvement in survival compared to surgery alone (adjusted hazard ratio [aHR], 0.50; 95% confidence interval [95% CI], 0.32‐0.81). On subgroup analysis, PORT was associated with improved survival for tumors 2 cm (aHR, 0.47; 95% CI, 0.29‐0.77), but not for tumors < 2 cm (aHR, 1.15; 95% CI, 0.33‐4.08).

Conclusion

The vast majority of patients with pT4aN0 bone‐invading SCC of the maxillary gingiva and hard palate benefit from PORT. Patients with tumors < 2 cm did not demonstrate a survival benefit from adjuvant treatment, suggesting that bony invasion alone may not be sufficient criteria for treatment escalation.

Subjects

MeSH terms (MEDLINE)

MaxillaCarcinoma, Squamous CellHumansMaleFemaleAgedRetrospective StudiesRadiotherapy, AdjuvantNeoplasm StagingMaxillary NeoplasmsMiddle AgedPalatal NeoplasmsPalate, HardGingival NeoplasmsSurvival RateNeck Dissection

Author keywords

adjuvant radiotherapyhead and neck cancermaxillectomypostoperative radiationsquamous cell carcinoma

Authors and institutions

  • Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Department of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.

ORCID profiles: Randall J Harley

Cite

APA

Harley, R. J., Spector, M. E., Wilke, C. T., & Sridharan, S. (2024). Postoperative Radiotherapy in Advanced Stage Squamous Cell Carcinoma Requiring Maxillectomy. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.896

Vancouver

Harley RJ, Spector ME, Wilke CT, Sridharan S. Postoperative Radiotherapy in Advanced Stage Squamous Cell Carcinoma Requiring Maxillectomy. Otolaryngology–Head and Neck Surgery. 2024. doi:10.1002/ohn.896

BibTeX
@article{Harley2024,
  author = {Harley, Randall J and Spector, Matthew E and Wilke, Christopher T and Sridharan, Shaum},
  title = {Postoperative Radiotherapy in Advanced Stage Squamous Cell Carcinoma Requiring Maxillectomy},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2024},
  doi = {10.1002/ohn.896}
}
Start for free →